EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment.

about

EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment.

Item

http://www.wikidata.org/entity/Q35921909

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment.

@ast

EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment.

@en

type

Item

label

EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment.

@ast

EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment.

@en

prefLabel

EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment.

@ast

EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment.

@en

P1476

EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment.

@en

P2093

Alec Miners

http://www.w3.org/2001/XMLSchema#string

Andrew Ustianowski

http://www.w3.org/2001/XMLSchema#string

Björn Vandewalle

http://www.w3.org/2001/XMLSchema#string

Colette Smith

http://www.w3.org/2001/XMLSchema#string

Diana Ferreira

http://www.w3.org/2001/XMLSchema#string

Jorge Félix

http://www.w3.org/2001/XMLSchema#string

Josep M Llibre

http://www.w3.org/2001/XMLSchema#string

Ricardo Camacho

http://www.w3.org/2001/XMLSchema#string

P2860

How does HIV cause AIDS?

Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach

ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia

Modelling HIV and MTB co-infection including combined treatment strategies

Patterns of transmitted HIV drug resistance in Europe vary by risk group

Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels.

The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials.

Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States

Determinants of sexual network structure and their impact on cumulative network measures.

Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal.

P304

e0149007

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0149007

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Jacques Parienti

P577

2016-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

294258122

http://www.w3.org/2001/XMLSchema#string

P698

26870960

http://www.w3.org/2001/XMLSchema#string

P932

4752501

http://www.w3.org/2001/XMLSchema#string